Needle length for epinephrine prefilled syringes in children and adolescents: Is it one inch?

Manuyakorn, Wiparat; Bamrungchaowkasem, Buntita; Ruangwattanapaisarn, Nichanan; Kamchaisatian, Wasu; Benjaponpitak, Suwat

doi:10.12932/ap-020317-0039

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 However, in another paediatric study where a slightly longer needle was used as the reference (25.4 mm), again with no pressure being applied during USS, the risk of periosteal/IO injection was as high as 12% in those aged 2-5 years. 32 Apart from needle length, the other risk factors for adrenaline being administered SC, and not IM, were an increased BMI 6,25,26,28,29,[32][33][34] and female sex for adults (independent of BMI). 6,29,33 Johnstone et al 29 reported in their study that 87% of females were at risk of SC injection compared to 0% of males.…”

Section: Imaging Studiesmentioning

confidence: 99%

Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto‐injector for anaphylactic reactions: A review of literature

Moss

Jani

Edwards³

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Anaphylaxis is a severe allergic reaction that can lead to death if not treated quickly. Adrenaline (epinephrine) is the first‐line treatment for anaphylaxis and its prompt administration is vital to reduce mortality. Following a number of high‐profile cases, serious concerns have been raised, both about the optimal dose of intramuscular adrenaline via an auto‐injector and the correct needle length to ensure maximal penetration every time. To date, the public data are sparse on the pharmacokinetics–pharmacodynamics of adrenaline administered via an auto‐injector. The limited available literature showed a huge variation in the plasma concentrations of adrenaline administered through an auto‐injector, as well as variations in the auto‐injector needle length. Hence, delivering an effective dose during an anaphylaxis remains a challenge for both patients and healthcare professionals. Collaborative work between pharmacokinetics–pharmacodynamics experts, clinical triallists and licence holders is imperative to address this gap in evidence so that we can improve outcomes of anaphylaxis. In addition, we advise inclusion of expertise of human factors in usability studies given the necessity of carer or self‐administration in the uniquely stressful nature of anaphylaxis.

show abstract

Section: Imaging Studiesmentioning

confidence: 99%

Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto‐injector for anaphylactic reactions: A review of literature

Moss

Jani

Edwards³

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Needle length for epinephrine prefilled syringes in children and adolescents: Is it one inch?

Abstract: Background: Intramuscular epinephrine is the first line drug in the treatment of anaphylaxis. This study was to identify the appropriateness of 1 inch needle length for epinephrine prefilled syringes in children.

Cited by 1 publication

References 17 publications

Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto‐injector for anaphylactic reactions: A review of literature

Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto‐injector for anaphylactic reactions: A review of literature

Contact Info

Product

Resources

About